![PK – PD model structure. E max is the maximal increase of prolactin... | Download Scientific Diagram PK – PD model structure. E max is the maximal increase of prolactin... | Download Scientific Diagram](https://www.researchgate.net/publication/51577100/figure/fig1/AS:277482600189954@1443168416062/PK-PD-model-structure-E-max-is-the-maximal-increase-of-prolactin-under-spiradoline.png)
PK – PD model structure. E max is the maximal increase of prolactin... | Download Scientific Diagram
![IJMS | Free Full-Text | Distinct Effects of Nalmefene on Dopamine Uptake Rates and Kappa Opioid Receptor Activity in the Nucleus Accumbens Following Chronic Intermittent Ethanol Exposure IJMS | Free Full-Text | Distinct Effects of Nalmefene on Dopamine Uptake Rates and Kappa Opioid Receptor Activity in the Nucleus Accumbens Following Chronic Intermittent Ethanol Exposure](https://pub.mdpi-res.com/ijms/ijms-17-01216/article_deploy/html/images/ijms-17-01216-ag.png?1581074634)
IJMS | Free Full-Text | Distinct Effects of Nalmefene on Dopamine Uptake Rates and Kappa Opioid Receptor Activity in the Nucleus Accumbens Following Chronic Intermittent Ethanol Exposure
![Elevated Prolactin during Pregnancy Drives a Phenotypic Switch in Mouse Hypothalamic Dopaminergic Neurons - ScienceDirect Elevated Prolactin during Pregnancy Drives a Phenotypic Switch in Mouse Hypothalamic Dopaminergic Neurons - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2211124719300968-fx1.jpg)
Elevated Prolactin during Pregnancy Drives a Phenotypic Switch in Mouse Hypothalamic Dopaminergic Neurons - ScienceDirect
![Prolactin release caused by the morphinan compound nalfurafine. All bar... | Download Scientific Diagram Prolactin release caused by the morphinan compound nalfurafine. All bar... | Download Scientific Diagram](https://www.researchgate.net/publication/341533406/figure/fig5/AS:941386115321892@1601455348844/Prolactin-release-caused-by-the-morphinan-compound-nalfurafine-All-bar-graphs-are-shown.png)
Prolactin release caused by the morphinan compound nalfurafine. All bar... | Download Scientific Diagram
![Kappa Opioid Receptor Antagonists as Potential Therapeutics for Mood and Substance Use Disorders | SpringerLink Kappa Opioid Receptor Antagonists as Potential Therapeutics for Mood and Substance Use Disorders | SpringerLink](https://media.springernature.com/lw685/springer-static/image/chp%3A10.1007%2F164_2020_401/MediaObjects/500126_1_En_401_Fig1_HTML.png)
Kappa Opioid Receptor Antagonists as Potential Therapeutics for Mood and Substance Use Disorders | SpringerLink
![A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0223523422006870-ga1.jpg)
A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect
![Hyperprolactinemia associated with psychotropics—a review - Madhusoodanan - 2010 - Human Psychopharmacology: Clinical and Experimental - Wiley Online Library Hyperprolactinemia associated with psychotropics—a review - Madhusoodanan - 2010 - Human Psychopharmacology: Clinical and Experimental - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/9cf3a577-20ea-4ecb-9b7d-82ad3f4d26c4/mfig001.jpg)
Hyperprolactinemia associated with psychotropics—a review - Madhusoodanan - 2010 - Human Psychopharmacology: Clinical and Experimental - Wiley Online Library
Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140) | Journal of Medicinal Chemistry
![Characterization of a Knock-In Mouse Line Expressing a Fusion Protein of κ Opioid Receptor Conjugated with tdTomato: 3-Dimensional Brain Imaging via CLARITY | eNeuro Characterization of a Knock-In Mouse Line Expressing a Fusion Protein of κ Opioid Receptor Conjugated with tdTomato: 3-Dimensional Brain Imaging via CLARITY | eNeuro](https://www.eneuro.org/content/7/4/ENEURO.0028-20.2020/F1.large.jpg)
Characterization of a Knock-In Mouse Line Expressing a Fusion Protein of κ Opioid Receptor Conjugated with tdTomato: 3-Dimensional Brain Imaging via CLARITY | eNeuro
![PK – PD model structure. E max is the maximal increase of prolactin... | Download Scientific Diagram PK – PD model structure. E max is the maximal increase of prolactin... | Download Scientific Diagram](https://www.researchgate.net/profile/Sarah-Grimwood/publication/51577100/figure/fig1/AS:277482600189954@1443168416062/PK-PD-model-structure-E-max-is-the-maximal-increase-of-prolactin-under-spiradoline_Q640.jpg)
PK – PD model structure. E max is the maximal increase of prolactin... | Download Scientific Diagram
![Mu and kappa opioid receptor expression in the mediobasal hypothalamus and effectiveness of selective antagonists on prolactin release during lactation - ScienceDirect Mu and kappa opioid receptor expression in the mediobasal hypothalamus and effectiveness of selective antagonists on prolactin release during lactation - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0306452209021563-gr2.jpg)
Mu and kappa opioid receptor expression in the mediobasal hypothalamus and effectiveness of selective antagonists on prolactin release during lactation - ScienceDirect
![Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence | Neuropsychopharmacology Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence | Neuropsychopharmacology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fnpp.2017.205/MediaObjects/41386_2018_Article_BFnpp2017205_Fig1_HTML.jpg)
Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence | Neuropsychopharmacology
![Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence | Neuropsychopharmacology Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence | Neuropsychopharmacology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fnpp.2017.205/MediaObjects/41386_2018_Article_BFnpp2017205_Fig2_HTML.jpg)
Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence | Neuropsychopharmacology
![Mu and kappa opioid receptor expression in the mediobasal hypothalamus and effectiveness of selective antagonists on prolactin release during lactation - ScienceDirect Mu and kappa opioid receptor expression in the mediobasal hypothalamus and effectiveness of selective antagonists on prolactin release during lactation - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0306452209021563-gr3.jpg)
Mu and kappa opioid receptor expression in the mediobasal hypothalamus and effectiveness of selective antagonists on prolactin release during lactation - ScienceDirect
![Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence | Neuropsychopharmacology Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence | Neuropsychopharmacology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fnpp.2017.205/MediaObjects/41386_2018_Article_BFnpp2017205_Fig3_HTML.jpg)
Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence | Neuropsychopharmacology
![Neuroendocrine Regulation of Prolactin Secretion During Late Pregnancy: Easing the Transition into Lactation - Andrews - 2005 - Journal of Neuroendocrinology - Wiley Online Library Neuroendocrine Regulation of Prolactin Secretion During Late Pregnancy: Easing the Transition into Lactation - Andrews - 2005 - Journal of Neuroendocrinology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/ed07d458-aaa3-43ac-aead-1310d75a8ba5/jne_1327_f1.gif)
Neuroendocrine Regulation of Prolactin Secretion During Late Pregnancy: Easing the Transition into Lactation - Andrews - 2005 - Journal of Neuroendocrinology - Wiley Online Library
![Dynorphin A1–13 Causes Elevation of Serum Levels of Prolactin Through an Opioid Receptor Mechanism in Humans: Gender Differences and Implications for Modulation of Dopaminergic Tone in the Treatment of Addictions | Journal Dynorphin A1–13 Causes Elevation of Serum Levels of Prolactin Through an Opioid Receptor Mechanism in Humans: Gender Differences and Implications for Modulation of Dopaminergic Tone in the Treatment of Addictions | Journal](https://jpet.aspetjournals.org/content/jpet/288/1/260/F4.large.jpg)
Dynorphin A1–13 Causes Elevation of Serum Levels of Prolactin Through an Opioid Receptor Mechanism in Humans: Gender Differences and Implications for Modulation of Dopaminergic Tone in the Treatment of Addictions | Journal
![Preclinical evaluation of the kappa-opioid receptor antagonist CERC-501 as a candidate therapeutic for alcohol use disorders | Neuropsychopharmacology Preclinical evaluation of the kappa-opioid receptor antagonist CERC-501 as a candidate therapeutic for alcohol use disorders | Neuropsychopharmacology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41386-018-0015-y/MediaObjects/41386_2018_15_Fig1_HTML.jpg)